ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2025 | -$0.17 | -$0.09 | Beat |
| May 8, 2025 | -$0.19 | -$0.14 | Beat |
| Feb 11, 2025 | -$0.18 | -$0.19 | Miss |
| Dec 17, 2024 | -$0.19 | -$0.14 | Beat |
| Aug 5, 2024 | -$0.26 | -$0.16 | Beat |
| May 14, 2024 | -$0.19 | -$0.20 | Miss |